Briacell TherapeuticsBCTX

13F holders, Q3 2024 (September 30)
22holders +2
6new positions
4sold out
$1.20avg. 13F price*

At the end of Q3 2024, 22 institutions reported holding Briacell Therapeutics Corp. (BCTX) in their 13F filings, up 2 from Q2 2024. 6 opened new positions and 4 sold out. The largest holders were Vontobel Holding Ltd. ($99K), HRT Financial LP ($92K) and Onyx Bridge Wealth Group LLC ($62K).

Company
Briacell Therapeutics Corp.
CUSIP
107930109
Latest filing quarter
Q4 2024

History

Number of 13F holders

0102030 Q1 2024: 19Q1 2024Q2 2024: 20Q2 2024Q3 2024: 22Q3 2024Q4 2024: 26Q4 2024

Total Exit/New Position Q2 2024 → Q3 2024

InstitutionsTotal Value
New Positions6$213K
Exits4$160K

All 13F filers, Q2 2024 → Q3 2024: 237,348 shares bought and 180,055 shares sold, net +57,293 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 22 holders

Vontobel Holding Ltd. 0.00% New 80,000 $99K
HRT Financial LP 0.00% New 74,286 $92K
Onyx Bridge Wealth Group LLC 0.01% No change 50,000 $62K
Group One Trading LLC 0.00% Add +247.8% 37,885 $47K
Summit Trail Advisors, LLC 0.00% No change 35,000 $43K
LPL Financial LLC 0.00% Add +161.8% 30,259 $38K
XTX Topco Ltd 0.00% Add +113.7% 26,422 $33K
Bank of Montreal 0.00% Reduce -37.3% 35,330 $27K
Cambridge Investment Research Advisors, Inc. 0.00% New 16,300 $20K
HighTower Advisors, LLC 0.00% Reduce -0.7% 14,628 $18K
Concord Wealth Partners 0.00% Add +36.6% 14,076 $17K
Susquehanna International Group, LLP 0.00% Add +12.5% 13,899 $17K
National Bank of Canada 0.00% Add +3.8% 7,788 $10K
Royal Bank of Canada 0.00% Reduce -0.5% 3,813 $5K
Morgan Stanley 0.00% No change 2,658 $3K
TD Waterhouse Canada Inc. 0.00% Reduce -17.4% 2,850 $2K
HHM Wealth Advisors, LLC 0.00% No change 1,000 $1K
Osaic Holdings, Inc. 0.00% Reduce -2.5% 1,000 $1K
UBS Group AG 0.00% New 794 $985
Wells Fargo & Company 0.00% New 290 $360
Bank of America Corp. 0.00% Reduce -99.9% 15 $19
Simplex Trading, LLC 0.00% New 323 $0

"% of holder's portfolio" is BCTX's weight in each manager's 13F, not the share of Briacell Therapeutics Corp. the manager owns.